J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?

• click to rate

  Posted by Two Blokes Jul 18 - Filed in Stock - 5 views
  
  JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.